Skip to main content
Home

Top menu

  • Careers
  • Giving
  • Intranet
Search
  • About us
      1. This is Broad Learn about our mission, our values, our history, and partner institutions.
      2. People Meet our members, staff scientists, fellows, leadership, and other Broadies.
      3. Join Broad Find out how to join the Broad as an employee or associate member.
      4. Contact us Find our contact information, directions to our buildings, and directory.
      5. Broad@20 Broad turns 20 this year! See how we’re celebrating our 20th anniversary.
  • Research
      1. Disease areas Broad brings people together to advance the understanding and treatment of disease.
        1. Items Wpapp col
          • Cancer
          • Cardiovascular disease
          • Brain Health
          • Diabetes
          • Infectious disease and microbiome
          • Kidney disease
          • Obesity
          • Rare disease
      2. Research areas Through programs spanning genetics, biology, and therapeutic development, Broad researchers are making discoveries that drive biomedical science forward.
        1. Items Wpapp col
          • Chemical biology and therapeutics science
          • Drug discovery
          • Genome regulation, cellular circuitry, and epigenomics
          • Immunology
          • Medical and population genetics
          • Metabolism
      3. Technology areas Our researchers use their expertise in creating, adapting, and applying a variety of technologies to enable science here and beyond.
        1. Items Wpapp col
          • Data sciences
          • Genetic perturbation
          • Genomics
          • Imaging
          • Metabolomics
          • Proteomics
          • Spatial technologies
      4. Science
        1. Patient-partnered research Patients partner with our scientists to accelerate the pace of discovery and find better treatments.
        2. Partnering and licensing We work closely with pharmaceutical, biotech, and technology partners to accelerate the translation of our discoveries.
        3. Publications A catalog of scientific papers published by our members and staff scientists.
        4. Resources, services, and tools Key scientific datasets and computational tools developed by our scientists and their collaborators.
        5. Collaborations and consortia We join with institutions and scientists the world over to address foundational challenges in science and health.
  • Centers
      1. Carlos Slim Center for Health Research The Slim Center aims to bring the benefits of genomics-driven medicine to Latin America, gleaning new insights into diseases with relevance to the region.
      2. Gerstner Center for Cancer Diagnostics The Gerstner Center is developing next-generation diagnostic technology for cancer detection and tracking disease progression.
      3. Klarman Cell Observatory The Klarman Cell Observatory is systematically defining mammalian cellular circuits, how they work together to create tissues and organs, and are perturbed to cause disease.
      4. Merkin Institute for Transformative Technologies in Healthcare The Merkin Institute is supporting early-stage ideas aimed at advancing powerful technological approaches for improving how we understand and treat disease.
      5. Novo Nordisk Foundation Center for Genomic Mechanisms of Disease This center is developing new paradigms and technologies to scale the discovery of biological mechanisms of common, complex diseases, by facilitating close collaborations between the Broad Institute and the Danish research community.
      6. Eric and Wendy Schmidt Center The EWSC is catalyzing a new field of interdisciplinary research at the intersection of data science and life science, aimed at improving human health.
      7. Stanley Center for Psychiatric Research The Stanley Center aims to reduce the burden of serious mental illness by contributing new insights into pathogenesis, identifying biomarkers, and paving the way toward new treatments.
  • Education and outreach
      1. Art and science connection Explore the connection between art and science and how we bring together artists and Broad scientists through our artist-in-residence program, gallery exhibitions, and ongoing public conversations.
      2. Broad Discovery Center Visit our free public educational space that showcases how researchers at the Broad and their colleagues around the world seek to understand and treat human disease.
      3. Learning resources Access free classroom materials and more for STEM educators, parents, students, tutors, and others.
      4. Public programs Discover remarkable stories of scientific progress, and explore the intersections of science, medicine, and society.
      5. Student opportunities Learn about Broad Institute's mentored research offerings for high school students, college students, and recent college graduates.
      6. Visit Broad Come see what Broad is all about.
  • News
      1. News and insights Learn about breakthroughs from Broad scientists.
        1. Column
      2. Press room Contact our media relations team.
        1. Column
      3. Sign up for our newsletter Receive regular updates on Broad news, research and community.
  • Careers
  • Giving
  • Intranet
  • Search
An oxindole efflux inhibitor potentiates azoles and impairs virulence in the fungal pathogen Candida auris.
Iyer KR, Camara K, Daniel-Ivad M, et al. An oxindole efflux inhibitor potentiates azoles and impairs virulence in the fungal pathogen Candida auris. Nat Commun. 2020;11(1):6429. doi:10.1038/s41467-020-20183-3DOIGoogle ScholarPubMed
Read more
Experimental Evolution Identifies Adaptive Aneuploidy as a Mechanism of Fluconazole Resistance in Candida auris.
Bing J, Hu T, Zheng Q, Muñoz JF, Cuomo CA, Huang G. Experimental Evolution Identifies Adaptive Aneuploidy as a Mechanism of Fluconazole Resistance in Candida auris. Antimicrob Agents Chemother. 2020;65(1). doi:10.1128/AAC.01466-20DOIGoogle ScholarPubMed
Read more
Overcoming fluconazole resistance in Candida albicans clinical isolates with tetracyclic indoles.
Youngsaye W, Dockendorff C, Vincent B, et al. Overcoming fluconazole resistance in Candida albicans clinical isolates with tetracyclic indoles. Bioorg Med Chem Lett. 2012;22(9):3362-5. doi:10.1016/j.bmcl.2012.02.035DOIGoogle ScholarPubMed
Read more
Piperazinyl quinolines as chemosensitizers to increase fluconazole susceptibility of Candida albicans clinical isolates.
Youngsaye W, Vincent B, Hartland CL, et al. Piperazinyl quinolines as chemosensitizers to increase fluconazole susceptibility of Candida albicans clinical isolates. Bioorg Med Chem Lett. 2011;21(18):5502-5. doi:10.1016/j.bmcl.2011.06.105DOIGoogle ScholarPubMed
Read more
Characterization of plant-derived saponin natural products against Candida albicans.
Coleman JJ, Okoli I, Tegos GP, et al. Characterization of plant-derived saponin natural products against Candida albicans. ACS Chem Biol. 2010;5(3):321-32. doi:10.1021/cb900243bDOIGoogle ScholarPubMed
Read more
A CRISPR-Cas9-based gene drive platform for genetic interaction analysis in Candida albicans.
Shapiro RS, Chavez A, Porter CBM, et al. A CRISPR-Cas9-based gene drive platform for genetic interaction analysis in Candida albicans. Nat Microbiol. 2018;3(1):73-82. doi:10.1038/s41564-017-0043-0DOIGoogle ScholarPubMed
Read more
Mutations in TAC1B: a Novel Genetic Determinant of Clinical Fluconazole Resistance in Candida auris.
Rybak JM, Muñoz JF, Barker KS, et al. Mutations in TAC1B: a Novel Genetic Determinant of Clinical Fluconazole Resistance in Candida auris. mBio. 2020;11(3). doi:10.1128/mBio.00365-20DOIGoogle ScholarPubMed
Read more
The evolution of drug resistance in clinical isolates of Candida albicans.
Ford CB, Funt JM, Abbey D, et al. The evolution of drug resistance in clinical isolates of Candida albicans. Elife. 2015;4:e00662. doi:10.7554/eLife.00662DOIGoogle ScholarPubMed
Read more

Address

Merkin Building
415 Main St.
Cambridge, MA 02142

Follow Us

  • Twitter
  • Facebook
  • YouTube
  • Instagram
  • Linkedin
  • Threads
Home

Sign up for our newsletter

Did you know?

In March of 2020, Broad Institute converted a clinical genetics processing lab into a large-scale COVID-19 testing facility in less than two weeks.

We've screened more than 1,275 cancer cell lines as part of the Cancer Dependency Map (DepMap).

Broad Genomics Platform sequences a whole human genome every four minutes.

More than 11,000 individuals living with cancer in the United States and Canada have partnered with Count Me In to share their experiences and help accelerate cancer research.

The Drug Repurposing Hub is one of the most comprehensive and up-to-date biologically annotated collections of FDA-approved compounds in the world. Researchers anywhere can explore more than 6,000 drugs in the hub and search for possible new uses for them to jump-start new drug discovery.

In 2021, our sustainability efforts sent more than 80 percent of waste from the Genomics Platform to either a recycling facility or to an incineration plant that generates electricity.

Through Broad's Scientists in the Classroom program, Broad researchers visit every 8th grade classroom in Cambridge each year to talk about genetics and evolution.

Every summer, 18 high school students spend six weeks at Broad working side-by-side with mentors on cutting-edge research.

In November 2022, Broad’s Genomics Platform sequenced its 500,000th whole human genome, a mere four years after sequencing its 100,000th.

By the end of 2022, Broad’s COVID-19 testing lab had processed more than 37 million tests.

Working with Addgene, Broad Institute has shared CRISPR genome-editing reagents with researchers at more than 3,200 institutions in 76 countries.

The NeuroGAP-Psychosis project, a collaboration between the Stanley Center for Psychiatric Research and Harvard T.H. Chan School of Public Health to study the genetics of severe mental illness, has recruited more than 42,000 participants in Ethiopia, Kenya, Uganda, and South Africa.

Footer menu

  • Report a concern
  • Contact Us
  • Privacy Policy

© Broad Institute 2024